Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Inwards

Showing results (61-70 of 179) with videos related to

Pageof 18
Sort By:
Clinical Lymphoma & Myeloma|February 28, 2007
AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphomaShernan G Holtan, Luis F Porrata, Ivana N M Micallef, et al.
Transplantation and Cellular Therapy|December 23, 2022
Outcomes of Older Adults with Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Mayo Clinic Cohort AnalysisKitsada Wudhikarn, Bradley M Johnson, David J Inwards, et al.
The American Journal of Medicine|December 3, 2002
Stem cell transplantation for the management of primary systemic amyloidosisMorie A Gertz, Martha Q Lacy, Angela Dispenzieri, et al.
Cancer|November 14, 2006
A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphomaIvana N M Micallef, Brad S Kahl, Matthew J Maurer, et al.
Cancer|May 13, 2008
Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment GroupDavid J Inwards, Paul A S Fishkin, David W Hillman, et al.
Transplantation and Cellular Therapy|June 6, 2021
Infused Autograft Absolute Lymphocyte Count Predicts Superior Survival in Diffuse Large B Cell Lymphoma Patients Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation: A Matched Case-Control StudyLuis F Porrata, Edwin A Burgstaler, Jeffrey L Winters, et al.
The Lancet. Oncology|March 29, 2011
Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 studyStephen M Ansell, Hui Tang, Paul J Kurtin, et al.
Hematological Oncology|June 5, 2018
Quality of life at diagnosis predicts overall survival in patients with aggressive lymphomaCarrie A Thompson, Kathleen J Yost, Matthew J Maurer, et al.
Plastic and Reconstructive Surgery. Global Open|June 16, 2025
Young Adult and Adolescent Gender-affirming Care: Defining Perioperative ProtocolsCaitlyn C Belza, Gaby Sendek, Miriam Becker, et al.
Leukemia & Lymphoma|July 7, 2007
Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasoneLijo Simpson, Stephen M Ansell, Joseph P Colgan, et al.
Pageof 18

Showing results (61-70 of 179) with videos related to

Sort By:
Pageof 18
Clinical Lymphoma & Myeloma|February 28, 2007
AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphomaShernan G Holtan, Luis F Porrata, Ivana N M Micallef, et al.
Transplantation and Cellular Therapy|December 23, 2022
Outcomes of Older Adults with Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Mayo Clinic Cohort AnalysisKitsada Wudhikarn, Bradley M Johnson, David J Inwards, et al.
The American Journal of Medicine|December 3, 2002
Stem cell transplantation for the management of primary systemic amyloidosisMorie A Gertz, Martha Q Lacy, Angela Dispenzieri, et al.
Cancer|November 14, 2006
A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphomaIvana N M Micallef, Brad S Kahl, Matthew J Maurer, et al.
Cancer|May 13, 2008
Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment GroupDavid J Inwards, Paul A S Fishkin, David W Hillman, et al.
Transplantation and Cellular Therapy|June 6, 2021
Infused Autograft Absolute Lymphocyte Count Predicts Superior Survival in Diffuse Large B Cell Lymphoma Patients Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation: A Matched Case-Control StudyLuis F Porrata, Edwin A Burgstaler, Jeffrey L Winters, et al.
The Lancet. Oncology|March 29, 2011
Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 studyStephen M Ansell, Hui Tang, Paul J Kurtin, et al.
Hematological Oncology|June 5, 2018
Quality of life at diagnosis predicts overall survival in patients with aggressive lymphomaCarrie A Thompson, Kathleen J Yost, Matthew J Maurer, et al.
Plastic and Reconstructive Surgery. Global Open|June 16, 2025
Young Adult and Adolescent Gender-affirming Care: Defining Perioperative ProtocolsCaitlyn C Belza, Gaby Sendek, Miriam Becker, et al.
Leukemia & Lymphoma|July 7, 2007
Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasoneLijo Simpson, Stephen M Ansell, Joseph P Colgan, et al.
Pageof 18